Interlaboratory comparison investigations (ICI) and external quality assurance schemes (EQUAS) for cadmium in urine and blood: Results from the HBM4EU project

Nübler, Stefanie; López, Marta Esteban; Castaño, Argelia; Mol, Hans; Schäfer, Moritz; Haji-Abbas-Zarrabi, Karin; Bury, Daniel; Koch, Holger M.; Vaccher, Vincent; Antignac, Jean‐Philippe; Dvořáková, Darina; Hajšlová, Jana; Thomsen, Cathrine; Vorkamp, Katrin; Göen, Thomas

doi:10.1016/j.ijheh.2021.113711

Cited by 22 publications

(15 citation statements)

References 38 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…HBM4EU provided an opportunity to check and improve the analytical methods and facilitated capacity building in Europe. Results of the cadmium and FR ICI/EQUAS are described by Nübler et al and Dvorakova et al respectively ( Nubler et al, 2021 ; Dvorakova et al, 2021 ). All data coming from the joint HBM4EU survey have a data quality label assigned.…”

Section: Method: Aligning European Hbm Surveysmentioning

confidence: 94%

HBM4EU combines and harmonises human biomonitoring data across the EU, building on existing capacity – The HBM4EU survey

Gilles

Govarts

Rambaud

et al. 2021

International Journal of Hygiene and Environmental Health

Self Cite

View full text Add to dashboard Cite

As part of the Human Biomonitoring for Europe (HBM4EU) initiative a human biomonitoring (HBM) survey is conducted in 21 countries. This survey builds on existing HBM capacity in Europe by aligning national or regional HBM studies. The survey targets 3 age groups (i) children aged 6–11 years, (ii) teenagers aged 12–19 years and (iii) young adults aged 20–39 years and includes a total of 9493 participants (3151 children, 2953 teenagers and 3389 young adults). Depending on the age group, internal exposure to phthalates and substitute Hexamoll® DINCH, brominated and organophosphorus flame retardants, per-/poly-fluorinated compounds, cadmium, bisphenols and/or polycyclic aromatic hydrocarbons are assessed. The main goal of the programme is to obtain quality controlled and comparable HBM data of exposure to chemicals, prioritized under HBM4EU, with European wide coverage to inform the development of environment and health policies. This paper describes the framework of the HBM4EU survey and the approach that has been applied to align European HBM initiatives across Europe.

show abstract

Section: Method: Aligning European Hbm Surveysmentioning

confidence: 94%

HBM4EU combines and harmonises human biomonitoring data across the EU, building on existing capacity – The HBM4EU survey

Gilles

Govarts

Rambaud

et al. 2021

International Journal of Hygiene and Environmental Health

Self Cite

View full text Add to dashboard Cite

show abstract

“…To safeguard the comparability of the data, analysis had to be performed in laboratories that successfully participated in the HBM4EU QA/QC program [ 21 ]. The laboratories could choose for which analytes they participated in the QA/QC program and the analytical qualification was evaluated at the metabolite level [ 42 , 43 ]. As a result, the biomarkers for which data are available differ somewhat per PSU.…”

Section: Methodsmentioning

confidence: 99%

Harmonization of Human Biomonitoring Studies in Europe: Characteristics of the HBM4EU-Aligned Studies Participants

Gilles

Govarts

Martín

et al. 2022

IJERPH

Self Cite

View full text Add to dashboard Cite

Human biomonitoring has become a pivotal tool for supporting chemicals’ policies. It provides information on real-life human exposures and is increasingly used to prioritize chemicals of health concern and to evaluate the success of chemical policies. Europe has launched the ambitious REACH program in 2007 to improve the protection of human health and the environment. In October 2020 the EU commission published its new chemicals strategy for sustainability towards a toxic-free environment. The European Parliament called upon the commission to collect human biomonitoring data to support chemical’s risk assessment and risk management. This manuscript describes the organization of the first HBM4EU-aligned studies that obtain comparable human biomonitoring (HBM) data of European citizens to monitor their internal exposure to environmental chemicals. The HBM4EU-aligned studies build on existing HBM capacity in Europe by aligning national or regional HBM studies. The HBM4EU-aligned studies focus on three age groups: children, teenagers, and adults. The participants are recruited between 2014 and 2021 in 11 to 12 primary sampling units that are geographically distributed across Europe. Urine samples are collected in all age groups, and blood samples are collected in children and teenagers. Auxiliary information on socio-demographics, lifestyle, health status, environment, and diet is collected using questionnaires. In total, biological samples from 3137 children aged 6–12 years are collected for the analysis of biomarkers for phthalates, HEXAMOLL® DINCH, and flame retardants. Samples from 2950 teenagers aged 12–18 years are collected for the analysis of biomarkers for phthalates, Hexamoll® DINCH, and per- and polyfluoroalkyl substances (PFASs), and samples from 3522 adults aged 20–39 years are collected for the analysis of cadmium, bisphenols, and metabolites of polyaromatic hydrocarbons (PAHs). The children’s group consists of 50.4% boys and 49.5% girls, of which 44.1% live in cities, 29.0% live in towns/suburbs, and 26.8% live in rural areas. The teenagers’ group includes 50.6% girls and 49.4% boys, with 37.7% of residents in cities, 31.2% in towns/suburbs, and 30.2% in rural areas. The adult group consists of 52.6% women and 47.4% men, 71.9% live in cities, 14.2% in towns/suburbs, and only 13.4% live in rural areas. The study population approaches the characteristics of the general European population based on age-matched EUROSTAT EU-28, 2017 data; however, individuals who obtained no to lower educational level (ISCED 0–2) are underrepresented. The data on internal human exposure to priority chemicals from this unique cohort will provide a baseline for Europe’s strategy towards a non-toxic environment and challenges and recommendations to improve the sampling frame for future EU-wide HBM surveys are discussed.

show abstract

“…The standard deviation for proficiency assessment was set at 25%. Detailed results of Cr ICI studies are described by Nübler et al (2021).…”

Section: Blood Sample Analysismentioning

confidence: 99%

HBM4EU chromates study - Usefulness of measurement of blood chromium levels in the assessment of occupational Cr(VI) exposure.

Ndaw

Leso

Bousoumah

et al. 2022

Environmental Research

View full text Add to dashboard Cite

Interlaboratory comparison investigations (ICI) and external quality assurance schemes (EQUAS) for cadmium in urine and blood: Results from the HBM4EU project

Cited by 22 publications

References 38 publications

HBM4EU combines and harmonises human biomonitoring data across the EU, building on existing capacity – The HBM4EU survey

HBM4EU combines and harmonises human biomonitoring data across the EU, building on existing capacity – The HBM4EU survey

Harmonization of Human Biomonitoring Studies in Europe: Characteristics of the HBM4EU-Aligned Studies Participants

HBM4EU chromates study - Usefulness of measurement of blood chromium levels in the assessment of occupational Cr(VI) exposure.

Contact Info

Product

Resources

About